Get started
LILLY DRNLILLY DRNLILLY DRN

LILLY DRN

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

LILY34 chart


Full chart

Key facts today

Daiwa lowered its price target on Eli Lilly & Co. to $900 from $940, keeping an outperform rating. Analysts show an average outperform rating with a price target range of $580 to $1,250.
Eli Lilly's Zyprexa peaked at $5 billion in 2010. Analysts suggest Bristol-Myers Squibb's Cobenfy could surpass this, potentially exceeding $10 billion in sales if it secures more indications.
Eli Lilly & Company experienced a Power Inflow on November 12th, indicating a significant trading signal at a price of $816.14.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪4.56 T‬ BRL
Dividend yield (indicated)
0.42%
Price to earnings Ratio (TTM)
6,808.12
Basic EPS (TTM)
0.02 BRL
Net income (FY)
‪26.18 B‬ BRL
Revenue (FY)
‪170.45 B‬ BRL
Shares float
—
Beta (1Y)
−0.07

About Eli Lilly and Company


Sector
Health Technology
CEO
David A. Ricks
Headquarters
Indianapolis
Website
lilly.com
Founded
1876
ISIN
BRLILYBDR006
FIGI
BBG002QBHFC7
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

LILY34 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

LILY34 highest yielding bonds


US532457AM0
ELI LILLY 2025
Yield to maturity
6.06%
Maturity date
Jun 1, 2025
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044
Yield to maturity
5.39%
Maturity date
Jun 15, 2044
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064
Yield to maturity
5.34%
Maturity date
Aug 14, 2064
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
Yield to maturity
5.28%
Maturity date
Feb 27, 2063
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054
Yield to maturity
5.26%
Maturity date
Feb 9, 2054
LLY5871803
Eli Lilly and Company 5.05% 14-AUG-2054
Yield to maturity
5.25%
Maturity date
Aug 14, 2054
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064
Yield to maturity
5.25%
Maturity date
Feb 9, 2064
LLY.GG
Eli Lilly and Company 6.77% 01-JAN-2036
Yield to maturity
5.23%
Maturity date
Jan 1, 2036
LLY5547404
Eli Lilly and Company 4.875% 27-FEB-2053
Yield to maturity
5.23%
Maturity date
Feb 27, 2053
US532457BS6
ELI LILLY 19/39
Yield to maturity
5.17%
Maturity date
Mar 15, 2039
LLY4492882
Eli Lilly and Company 3.95% 15-MAY-2047
Yield to maturity
5.16%
Maturity date
May 15, 2047

Explore more bonds 

Sparks


Curated watchlists where LILY34 is featured.

See all sparks